Toxicity of Androgen Deprivation Therapy in Hormone-Sensitive Prostate Cancer

  • Naveed H. Akhtar
  • Elan S. Diamond
  • Nicole Eiseler
  • Scott T. Tagawa


Androgen deprivation therapy for prostate cancer is one of the most effective types of systemic therapies in solid tumor malignancies and represents one of the first examples of “targeted therapy.” However, we have become increasingly aware of the adverse events associated with androgen deprivation therapy. Some of these side effects can have deleterious effects on quality of life, and others may contribute to increased risks for serious health concerns. Vasomotor toxicity (hot flashes) and sexual side effects are among the most well-recognized adverse effects. Additional toxicities related to the metabolic effects include bone and muscle changes, lipid and glucose metabolic changes, and cognitive changes, which are important to recognize. Physicians should be aware of profound effects of ADT and should incorporate strategies for preventing, identifying, and managing toxicities into routine practice. This chapter reviews the incidence and mechanism of each group of toxicities and discusses the potential primary and secondary therapeutic possibilities.


Prostate Cancer Bone Mineral Density Zoledronic Acid Androgen Deprivation Therapy Prostate Cancer Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002;167(2 Pt 2):948–51; discussion 952.PubMedCrossRefGoogle Scholar
  2. 2.
    Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735–52.PubMedCrossRefGoogle Scholar
  3. 3.
    Fortmann SP, Ford E, Criqui MH, et al. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the population science discussion group. Circulation. 2004;110(25):e554–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2009;181(5):1998–2006.PubMedCrossRefGoogle Scholar
  5. 5.
    Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer. 2006;106(3):581–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448–56.PubMedCrossRefGoogle Scholar
  7. 7.
    Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006;91(4):1305–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87(2):599–603.PubMedCrossRefGoogle Scholar
  9. 9.
    Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24(24):3979–83.PubMedCrossRefGoogle Scholar
  10. 10.
    Smith MR, Lee H, McGovern F, et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer. 2008;112(10):2188–94.PubMedCrossRefGoogle Scholar
  11. 11.
    Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007;116(1):39–48.PubMedCrossRefGoogle Scholar
  12. 12.
    Lindsay RS, Resnick HE, Zhu J, et al. Adiponectin and coronary heart disease: the strong heart study. Arterioscler Thromb Vasc Biol. 2005;25(3):e15–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care. 2000;23(4):490–4.PubMedCrossRefGoogle Scholar
  14. 14.
    Selvin E, Feinleib M, Zhang L, et al. Androgens and diabetes in men: results from the third national health and nutrition examination survey (NHANES III). Diabetes Care. 2007;30(2):234–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154(6):899–906.PubMedCrossRefGoogle Scholar
  16. 16.
    Alibhai SM, Duong-Hua M, Sutradhar R, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol. 2009;27(21):3452–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Derweesh IH, Diblasio CJ, Kincade MC, et al. Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer. BJU Int. 2007;100(5):1060–5.PubMedGoogle Scholar
  18. 18.
    Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330(7503):1304–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009;32(9):1620–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care. 2010;33(2):322–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Moorjani S, Dupont A, Labrie F, et al. Increase in plasma high-density lipoprotein concentration following complete androgen blockage in men with prostatic carcinoma. Metabolism. 1987;36(3):244–50.PubMedCrossRefGoogle Scholar
  22. 22.
    Eri LM, Urdal P, Bechensteen AG. Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. J Urol. 1995;154(1):100–4.PubMedCrossRefGoogle Scholar
  23. 23.
    Braga-Basaria M, Muller DC, Carducci MA, Dobs AS, Basaria S. Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. Int J Impot Res. 2006;18(5):494–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Smith MR, Malkowicz SB, Chu F, et al. Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. J Clin Oncol. 2008;26(11):1824–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Galvao DA, Spry N, Taaffe DR, et al. A randomized controlled trial of an exercise intervention targeting cardiovascular and metabolic risk factors for prostate cancer patients from the RADAR trial. BMC Cancer. 2009;9:419.PubMedCrossRefGoogle Scholar
  26. 26.
    Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab. 2008;93(1):68–75.PubMedCrossRefGoogle Scholar
  27. 27.
    Smith MR. Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors. Curr Urol Rep. 2008;9(3):197–202.PubMedCrossRefGoogle Scholar
  28. 28.
    Saigal CS, Gore JL, Krupski TL, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110(7):1493–500.PubMedCrossRefGoogle Scholar
  29. 29.
    Keating NL, O’Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010;102(1):39–46.PubMedCrossRefGoogle Scholar
  30. 30.
    D’Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007;25(17):2420–5.PubMedCrossRefGoogle Scholar
  31. 31.
    Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85–31. J Clin Oncol. 2009;27(1):92–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86–10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;50(5):1243–52.PubMedCrossRefGoogle Scholar
  33. 33.
    Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92–02. J Clin Oncol. 2003;21(21):3972–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Lu-Yao GL, Albertsen PC, Moore DF, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA. 2008;300(2):173–81.PubMedCrossRefGoogle Scholar
  35. 35.
    Levine GN, D’Amico AV, Berger P, Clark PE, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin. 2010;60(3):194–201.PubMedCrossRefGoogle Scholar
  36. 36.
    D’Amico AV, Loffredo M, Renshaw AA, Loffredo B, Chen MH. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level. J Clin Oncol. 2006;24(25):4190–5.PubMedCrossRefGoogle Scholar
  37. 37.
    D’Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs. radiation alone for prostate cancer: a randomized trial. JAMA. 2008;299(3):289–95.PubMedCrossRefGoogle Scholar
  38. 38.
    Fonseca R, Rajkumar SV, White WL, Tefferi A, Hoagland HC. Anemia after orchiectomy. Am J Hematol. 1998;59(3):230–3.PubMedCrossRefGoogle Scholar
  39. 39.
    Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol. 1997;79(6):933–41.PubMedCrossRefGoogle Scholar
  40. 40.
    Asbell SO, Leon SA, Tester WJ, Brereton HD, Ago CT, Rotman M. Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy. Prostate. 1996;29(4):243–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Albers P, Melchior D, Muller SC. Surgery in metastatic testicular cancer. Eur Urol. 2003;44(2):233–44.PubMedCrossRefGoogle Scholar
  42. 42.
    Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, editors. Williams textbook of endocrinology. 10th ed. Philadelphia: WB Saunders Co; 2002. p. 750.Google Scholar
  43. 43.
    Spivak JL. Recombinant human erythropoietin and the anemia of cancer. Blood. 1994;84(4):997–1004.PubMedGoogle Scholar
  44. 44.
    Nishiyama T, Ishizaki F, Anraku T, Shimura H, Takahashi K. The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. J Clin Endocrinol Metab. 2005;90(2):657–60.PubMedCrossRefGoogle Scholar
  45. 45.
    Johansson JE, Wersall P, Brandberg Y, Andersson SO, Nordstrom L. EPO-Study Group. Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer – a randomized study. Scand J Urol Nephrol. 2001;35(4):288–94.PubMedCrossRefGoogle Scholar
  46. 46.
    Wish JB, Coyne DW. Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies. Mayo Clin Proc. 2007;82(11):1371–80.PubMedCrossRefGoogle Scholar
  47. 47.
    Nishimura K, Nonomura N, Yasunaga Y, et al. Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer. 2000;89(12):2570–6.PubMedCrossRefGoogle Scholar
  48. 48.
    Mohile SG, Mustian K, Bylow K, Hall W, Dale W. Management of complications of androgen deprivation therapy in the older man. Crit Rev Oncol Hematol. 2009;70(3):235–55.PubMedCrossRefGoogle Scholar
  49. 49.
    Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299(8):914–24.PubMedCrossRefGoogle Scholar
  50. 50.
    Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol. 2000;163(1):181–6.Google Scholar
  51. 51.
    Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol. 1999;161(4):1219–22.PubMedCrossRefGoogle Scholar
  52. 52.
    Leder BZ, Smith MR, Fallon MA, Lee ML, Finkelstein JS. Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men. J Clin Endocrinol Metab. 2001;86(2):511–6.PubMedCrossRefGoogle Scholar
  53. 53.
    Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int. 1997;7:407–13.PubMedCrossRefGoogle Scholar
  54. 54.
    Bilezikian JP. Osteoporosis in men. J Clin Endocrinol Metab. 1999;84:3431–4.PubMedCrossRefGoogle Scholar
  55. 55.
    Smith MR, Boyce SP, Moyneur E, et al. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol. 2006;175:136–9.PubMedCrossRefGoogle Scholar
  56. 56.
    Shahinian VB, Kuo YF, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154–64.PubMedCrossRefGoogle Scholar
  57. 57.
    Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005;23(31):7897–903.PubMedCrossRefGoogle Scholar
  58. 58.
    Elliott SP, Jarosek SL, Alanee SR, Konety BR, Dusenbery KE, Virnig BA. Three-dimensional external beam radiotherapy for prostate cancer increases the risk of hip fracture. Cancer. doi: 10.1002/cncr.25994.
  59. 59.
    Waters DL, Baumgartner RN, Garry PJ. Sarcopenia: current perspectives. J Nutr Health Aging. 2000;4(3):133–9.PubMedGoogle Scholar
  60. 60.
    Morley JE, Baumgartner RN, Roubenoff R, Mayer J, Nair KS. Sarcopenia. J Lab Clin Med. 2001;137(4):231–43.PubMedCrossRefGoogle Scholar
  61. 61.
    Stone P, Hardy J, Huddart R, A’Hern R, Richards M. Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer. 2000;36(9):1134–41.PubMedCrossRefGoogle Scholar
  62. 62.
    Van Veldhuizen PJ, Taylor SA, Williamson S, Drees BM. Treatment of vitamin D deficiency in patients with metastatic prostate cancer may improve bone pain and muscle strength. J Urol. 2000;163(1):187–90.PubMedCrossRefGoogle Scholar
  63. 63.
    Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol. 2010;28(2):340–7.PubMedCrossRefGoogle Scholar
  64. 64.
    Diamond TH, Winters J, Smith A, et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer. 2001;92(6):1444–50.PubMedCrossRefGoogle Scholar
  65. 65.
    Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361(8):745–55.PubMedCrossRefGoogle Scholar
  66. 66.
    Smith MR, Morton RA, Barnette KG, et al. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2010;184(4):1316–21.PubMedCrossRefGoogle Scholar
  67. 67.
    Dearnaley DP, Sydes MR, Mason MD, et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst. 2003;95:1300–11.PubMedCrossRefGoogle Scholar
  68. 68.
    Dearnaley DP, Mason MD, Parmar MK, et al. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol. 2009;10:872–6.PubMedCrossRefGoogle Scholar
  69. 69.
    Zoledronate in Preventing Skeletal (Bone)-Related Events in Patients Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases.
  70. 70.
  71. 71.
    Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. 1997;337(10):670–6.PubMedCrossRefGoogle Scholar
  72. 72.
    Smith MR, Malkowicz SB, Chu F, et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol. 2008;179(1):152–5.PubMedCrossRefGoogle Scholar
  73. 73.
    Smith MR, Saad F, Egerdie B, et al. Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2009;182(6):2670–5.PubMedCrossRefGoogle Scholar
  74. 74.
    Kumar RJ, Barqawi A, Crawford ED. Adverse events associated with hormonal therapy for prostate cancer. Rev Urol. 2005;7 Suppl 5:S37–43.PubMedGoogle Scholar
  75. 75.
    Ferrari P, Castagnetti G, Ferrari G, Baisi B, Dotti A. Combination treatment versus LHRH alone in advanced prostatic cancer. Urol Int. 1996;56 Suppl 1:13–7.PubMedCrossRefGoogle Scholar
  76. 76.
    Langenstroer P, Porter 2nd HJ, McLeod DG, Thrasher JB. Direct gastrointestinal toxicity of flutamide: comparison of irradiated and nonirradiated cases. J Urol. 2004;171(2 Pt 1):684–6.PubMedCrossRefGoogle Scholar
  77. 77.
    Pervez N, Small C, MacKenzie M, et al. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2010;76(1):57–64.PubMedCrossRefGoogle Scholar
  78. 78.
    Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol. 2004;22(6):1025–33.PubMedCrossRefGoogle Scholar
  79. 79.
    Gomez JL, Dupont A, Cusan L, et al. Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients. Am J Med. 1992;92(5):465–70.PubMedCrossRefGoogle Scholar
  80. 80.
    Usami M, Akaza H, Arai Y, et al. Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients. Prostate Cancer Prostatic Dis. 2007;10(2):194–201.PubMedCrossRefGoogle Scholar
  81. 81.
    Davis NB, Ryan CW, Stadler WM, Vogelzang NJ. A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy. BJU Int. 2005;96(6):787–90.PubMedCrossRefGoogle Scholar
  82. 82.
    Ricker JM, Foody WF, Shumway NM, Shaw JC. Drug-induced liver injury caused by the histrelin (Vantus) subcutaneous implant. South Med J. 2010;103(1):84–6.PubMedCrossRefGoogle Scholar
  83. 83.
    Loblaw DA, Mendelson DS, Talcott JA, et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol. 2004;22(14):2927–41.PubMedCrossRefGoogle Scholar
  84. 84.
    Nelson CJ, Lee JS, Gamboa MC, Roth AJ. Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer. 2008;113(5):1097–106.PubMedCrossRefGoogle Scholar
  85. 85.
    Mohile SG, Lacy M, Rodin M, et al. Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer. Crit Rev Oncol Hematol. 2010;75(2):152–9.PubMedCrossRefGoogle Scholar
  86. 86.
    Alibhai SM, Breunis H, Timilshina N, Marzouk S, et al. Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer. J Clin Oncol. 2010;28(34):5030–7.PubMedCrossRefGoogle Scholar
  87. 87.
    Walker LM, Robinson JW. The unique needs of couples experiencing androgen deprivation therapy for prostate cancer. J Sex Marital Ther. 2010;36(2):154–65.PubMedCrossRefGoogle Scholar
  88. 88.
    Calais da Silva FE, Bono AV, Whelan P, et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol. 2009;55(6):1269–77.PubMedCrossRefGoogle Scholar
  89. 89.
    Flaig TW, Glode LM. Management of the side effects of androgen deprivation therapy in men with prostate cancer. Expert Opin Pharmacother. 2008;9(16):2829–41.PubMedCrossRefGoogle Scholar
  90. 90.
    Widmark A, Fosså SD, Lundmo P, Damber JE, Vaage S, Damber L, Wiklund F, Klepp O. Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3. Urology. 2003;61(1):145–51.PubMedCrossRefGoogle Scholar
  91. 91.
    Srinivasan V, Miree Jr J, Lloyd FA. Bilateral mastectomy and irradiation in the prevention of estrogen induced gynecomastia. J Urol. 1972;107(4):624–5.PubMedGoogle Scholar
  92. 92.
    Marberger M, Kaisary AV, Shore ND, et al. Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a phase III, open-label, international multicenter study. Clin Ther. 2010;32(4):744–57.PubMedCrossRefGoogle Scholar
  93. 93.
    Sakai H, Igawa T, Tsurusaki T, et al. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer. Urology. 2009;73(3):635–40.PubMedCrossRefGoogle Scholar
  94. 94.
    Irani J, Salomon L, Oba R, Bouchard P, Mottet N. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol. 2010;11(2):147–54.PubMedCrossRefGoogle Scholar
  95. 95.
    Moraska AR, Atherton PJ, Szydlo DW, et al. Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation Study-NCCTG Trial N00CB. J Support Oncol. 2010;8(3):128–32.PubMedGoogle Scholar
  96. 96.
    Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001;345(13):948–55.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  • Naveed H. Akhtar
    • 1
  • Elan S. Diamond
    • 2
  • Nicole Eiseler
    • 3
  • Scott T. Tagawa
    • 4
    • 5
  1. 1.Division of Hematology and Medical OncologyWeill Cornell Medical CollegeNew YorkUSA
  2. 2.Division of Hematology and Medical OncologyNew York Presbyterian Hospital, Weill Cornell Medical CollegeNew YorkUSA
  3. 3.Department of Internal MedicineSUNY DownstateBrooklynUSA
  4. 4.Division of Hematology and Medical OncologyWeill Cornell Medical CollegeNew YorkUSA
  5. 5.Department of UrologyNew York Presbyterian Hospital – Weill Cornell Medical CollegeNew YorkUSA

Personalised recommendations